Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23:1231–1251. https://doi.org/10.1093/neuonc/noab106%JNeuro-Oncology
CAS Article PubMed PubMed Central Google Scholar
Louis DN, Wesseling P, Paulus W, Giannini C, Batchelor TT, Cairncross JG, Capper D, Figarella-Branger D, Lopes MB, Wick W, van den Bent M (2018) cIMPACT-NOW update 1: not otherwise specified (NOS) and not elsewhere classified (NEC). Acta Neuropathol 135:481–484. https://doi.org/10.1007/s00401-018-1808-0
Brat DJ, Aldape K, Bridge JA, Canoll P, Colman H, Hameed MR, Harris BT, Hattab EM, Huse JT, Jenkins RB, Lopez-Terrada DH, McDonald WC, Rodriguez FJ, Souter LH, Colasacco C, Thomas NE, Yount MH, van den Bent MJ, Perry A (2022) Molecular biomarker testing for the diagnosis of diffuse gliomas. Arch Pathol Lab Med. https://doi.org/10.5858/arpa.2021-0295-CP
Article PubMed PubMed Central Google Scholar
Clocchiatti A, Cora E, Zhang Y, Dotto GP (2016) Sexual dimorphism in cancer. Nat Rev Cancer 16:330–339. https://doi.org/10.1038/nrc.2016.30
CAS Article PubMed Google Scholar
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330
CAS Article PubMed Google Scholar
Ostrom QT, Rubin JB, Lathia JD, Berens ME, Barnholtz-Sloan JS (2018) Females have the survival advantage in glioblastoma. Neuro Oncol 20:576–577. https://doi.org/10.1093/neuonc/noy002
Article PubMed PubMed Central Google Scholar
Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2017) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro Oncol 19:v1–v88. https://doi.org/10.1093/neuonc/nox158
Article PubMed PubMed Central Google Scholar
Shinojima N, Kochi M, Hamada J, Nakamura H, Yano S, Makino K, Tsuiki H, Tada K, Kuratsu J, Ishimaru Y, Ushio Y (2004) The influence of sex and the presence of giant cells on postoperative long-term survival in adult patients with supratentorial glioblastoma multiforme. J Neurosurg 101:219–226. https://doi.org/10.3171/jns.2004.101.2.0219
Ho VK, Reijneveld JC, Enting RH, Bienfait HP, Robe P, Baumert BG, Visser O (2014) Changing incidence and improved survival of gliomas. Eur J Cancer 50:2309–2318. https://doi.org/10.1016/j.ejca.2014.05.019
Dubrow R, Darefsky AS (2011) Demographic variation in incidence of adult glioma by subtype, United States, 1992–2007. BMC Cancer 11:325. https://doi.org/10.1186/1471-2407-11-325
Article PubMed PubMed Central Google Scholar
Ostrom QT, Cote DJ, Ascha M, Kruchko C, Barnholtz-Sloan JS (2018) Adult glioma incidence and survival by race or ethnicity in the United States from 2000 to 2014. JAMA Oncol 4:1254–1262. https://doi.org/10.1001/jamaoncol.2018.1789
Article PubMed PubMed Central Google Scholar
Claus EB, Black PM (2006) Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: data from the SEER program, 1973–2001. Cancer 106:1358–1363. https://doi.org/10.1002/cncr.21733
Yang W, Warrington NM, Taylor SJ, Whitmire P, Carrasco E, Singleton KW, Wu N, Lathia JD, Berens ME, Kim AH, Barnholtz-Sloan JS, Swanson KR, Luo J, Rubin JB (2019) Sex differences in GBM revealed by analysis of patient imaging, transcriptome, and survival data. Sci Transl Med. https://doi.org/10.1126/scitranslmed.aao5253
Article PubMed PubMed Central Google Scholar
Beig N, Singh S, Bera K, Prasanna P, Singh G, Chen J, Saeed Bamashmos A, Barnett A, Hunter K, Statsevych V, Hill VB, Varadan V, Madabhushi A, Ahluwalia MS, Tiwari P (2021) Sexually dimorphic radiogenomic models identify distinct imaging and biological pathways that are prognostic of overall survival in glioblastoma. Neuro Oncol 23:251–263. https://doi.org/10.1093/neuonc/noaa231
Tavelin B, Malmström A (2022) Sex differences in glioblastoma-findings from the Swedish national quality registry for primary brain tumors between 1999–2018. J Clin Med 11:486. https://doi.org/10.3390/jcm11030486
Article PubMed PubMed Central Google Scholar
Gittleman H, Ostrom QT, Stetson LC, Waite K, Hodges TR, Wright CH, Wright J, Rubin JB, Berens ME, Lathia J, Connor JR, Kruchko C, Sloan AE, Barnholtz-Sloan JS (2019) Sex is an important prognostic factor for glioblastoma but not for nonglioblastoma. Neuro-Oncol Pract 6:451–462. https://doi.org/10.1093/nop/npz019
Molenaar RJ, Verbaan D, Lamba S, Zanon C, Jeuken JWM, Boots-Sprenger SHE, Wesseling P, Hulsebos TJM, Troost D, van Tilborg AA, Leenstra S, Vandertop WP, Bardelli A, van Noorden CJF, Bleeker FE (2014) The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. Neuro Oncol 16:1263–1273. https://doi.org/10.1093/neuonc/nou005
CAS Article PubMed PubMed Central Google Scholar
Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350–1354. https://doi.org/10.1056/nejm200011093431901
CAS Article PubMed Google Scholar
Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JEC, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003. https://doi.org/10.1056/NEJMoa043331
CAS Article PubMed Google Scholar
Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773. https://doi.org/10.1056/NEJMoa0808710
CAS Article PubMed PubMed Central Google Scholar
Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M, von Deimling A (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120:707–718. https://doi.org/10.1007/s00401-010-0781-z
Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisselier B, Mokhtari K, Hoang-Xuan K, Delattre JY (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150–4154. https://doi.org/10.1200/jco.2009.21.9832
CAS Article PubMed Google Scholar
Wagner AD, Oertelt-Prigione S, Adjei A, Buclin T, Cristina V, Csajka C, Coukos G, Dafni U, Dotto GP, Ducreux M, Fellay J, Haanen J, Hocquelet A, Klinge I, Lemmens V, Letsch A, Mauer M, Moehler M, Peters S, Özdemir BC (2019) Gender medicine and oncology: report and consensus of an ESMO workshop. Ann Oncol 30:1914–1924. https://doi.org/10.1093/annonc/mdz414
CAS Article PubMed Google Scholar
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1
Park YW, Ahn SS, Park CJ, Han K, Kim EH, Kang SG, Chang JH, Kim SH, Lee SK (2020) Diffusion and perfusion MRI may predict EGFR amplification and the TERT promoter mutation status of IDH-wildtype lower-grade gliomas. Eur Radiol 30:6475–6484. https://doi.org/10.1007/s00330-020-07090-3
CAS Article PubMed Google Scholar
Na K, Kim HS, Shim HS, Chang JH, Kang SG, Kim SH (2019) Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases. J Neurooncol 142:445–454. https://doi.org/10.1007/s11060-019-03114-1
CAS Article PubMed Google Scholar
Hirsch FR, Varella-Garcia M, McCoy J, West H, Xavier AC, Gumerlock P, Bunn PA Jr, Franklin WA, Crowley J, Gandara DR (2005) Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 23:6838–6845. https://doi.org/10.1200/jco.2005.01.2823
CAS Article PubMed Google Scholar
Park YW, Han K, Ahn SS, Bae S, Choi YS, Chang JH, Kim SH, Kang SG, Lee SK (2018) Prediction of IDH1-mutation and 1p/19q-codeletion status using preoperative MR imaging phenotypes in lower grade gliomas. AJNR Am J Neuroradiol 39:37–42. https://doi.org/10.3174/ajnr.A5421
CAS Article PubMed PubMed Central Google Scholar
Nicolasjilwan M, Hu Y, Yan C, Meerzaman D, Holder CA, Gutman D, Jain R, Colen R, Rubin DL, Zinn PO, Hwang SN, Raghavan P, Hammoud DA, Scarpace LM, Mikkelsen T, Chen J, Gevaert O, Buetow K, Freymann J, Kirby J, Flanders AE, Wintermark M (2015) Addition of MR imaging features and genetic biomarkers strengthens glioblastoma survival prediction in TCGA patients. J Neuroradiol 42:212–221. https://doi.org/10.1016/j.neurad.2014.02.006
Schiffgens S, Wilkens L, Brandes AA, Meier T, Franceschi E, Ermani M, Hartmann C, Sandalcioglu IE, Dumitru CA (2016) Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma. Oncotarget 7:55169–55180. https://doi.org/10.18632/oncotarget.10465
Article PubMed PubMed Central Google Scholar
Smits A, Lysiak M, Magnusson A, Rosell J, Söderkvist P, Malmström A (2021) Sex disparities in MGMT promoter methylation and survival in glioblastoma: further evidence from clinical cohorts. J Clin Med 10:556. https://doi.org/10.3390/jcm10040556
CAS Article PubMed PubMed Central Google Scholar
Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, Anjum S, Wang J, Manyam G, Zoppoli P, Ling S, Rao AA, Grifford M, Cherniack AD, Zhang H, Poisson L, Carlotti CG Jr, Tirapelli DP, Rao A, Mikkelsen T, Lau CC, Yung WK, Rabadan R, Huse J, Brat DJ, Lehman NL, Barnholtz-Sloan JS, Zheng S, Hess K, Rao G, Meyerson M, Beroukhim R, Cooper L, Akbani R, Wrensch M, Haussler D, Aldape KD, Laird PW, Gutmann DH, Noushmehr H, Iavarone A, Verhaak RG (2016) Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164:550–563. https://doi.org/10.1016/j.cell.2015.12.028
留言 (0)